Study numberTumour typeStatusPhaseDetailsContactInfo
1.2021Any Anthracycline sensitive cancer which has an injectable tumourOpen and recruiting1Open-Label Study of SQ3370 in Patients with Advanced Solid Tumours Ph: 08 8359 2565 Fax: 08 7123 6170Study Info
2.2021Early stage breast cancer - for hormone blockadeOpen and recruiting3Randomized, open-label, study evaluating the efficacy and safety of adjuvant Giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in patient with Estrogen receptor positive, HER2 negative Early Breast Cancer - LiDERA Ph: 08 8359 2565 Fax: 08 7123 6170
3.2021Metastatic prostate cancer - which is hormone responsiveOpen and recruiting3Randomised, placebo controlled, double blind study of Darolutamide plus androgen deprivation therapy (ADT) VS ADT in subject with metastatic hormone sensitive prostate cancer (mHSPC) - Ph: 08 8359 2565 Fax: 08 7123 6170
Back to Top